Gaëtan Servais
Angel Investor @ Meusinvest (Noshaq)
Gaëtan Servais is a Series A investor at Meusinvest (Noshaq) focused on Health Care and Biotechnology. Gaëtan Servais is based out of Liège, Walloon Region and is the CEO of Noshaq.
- Total investments:
- 6
- Last investment:
- Lead investor:
- 17%
Last updated:
For AI agents: llms.txt
Industries Gaëtan Servais invests in
Stages Gaëtan Servais invests in
Countries Gaëtan Servais invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Health Care 2 (33%)
- Biotechnology 2 (33%)
- Medical 1 (17%)
- Biopharma 1 (17%)
- Power Grid 1 (17%)
Stage
- Series A 2 (33%)
- Series C 1 (17%)
- Venture - Series Unknown 1 (17%)
Country
- Belgium 2 (33%)
- Germany 1 (17%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Amyl Therapeutics is a preclinical stage biotechnology company. Amyl Therapeutics uses a novel mechanism to bind to the amyloid fold of toxic protein aggregates of various types, including antibody light chain (AL) or transthyretin (TTR) aggregates, which accumulate in peripheral organs to cause systemic amyloidosis diseases, but also amyloid-β(Aβ), Tau, and α-synuclein aggregates, which accumulate in the brain to cause Alzheimer's and Parkinson's diseases. | $9.6M / Series A / Sep 01, 2026 | ||
| Amyl Therapeutics is a preclinical stage biotechnology company. Amyl Therapeutics uses a novel mechanism to bind to the amyloid fold of toxic protein aggregates of various types, including antibody light chain (AL) or transthyretin (TTR) aggregates, which accumulate in peripheral organs to cause systemic amyloidosis diseases, but also amyloid-β(Aβ), Tau, and α-synuclein aggregates, which accumulate in the brain to cause Alzheimer's and Parkinson's diseases. | $5.7M / Series A / Nov 07, 2023 | ||
| Ampacimon develops dynamic line rating systems for transmission and distribution systems operators. Ampacimon’s products address grid infrastructure challenges such as aging assets, transmissions congestion, renewable integration, interconnectors. | $10.6M / Series C / Oct 16, 2023 | ||
| Amyl Therapeutics is a preclinical stage biotechnology company. Amyl Therapeutics uses a novel mechanism to bind to the amyloid fold of toxic protein aggregates of various types, including antibody light chain (AL) or transthyretin (TTR) aggregates, which accumulate in peripheral organs to cause systemic amyloidosis diseases, but also amyloid-β(Aβ), Tau, and α-synuclein aggregates, which accumulate in the brain to cause Alzheimer's and Parkinson's diseases. | $10.4M / Series A / Jun 03, 2021 | ||
| GeneQuine Biotherapeutics designs and develops gene therapies for its clients. The therapies developed by the company aim to treat osteoarthritis. Its product portfolio consists of GQ-201, GQ-202, and GQ-203. GeneQuine Biotherapeutics was founded in 2011 by Stanislav Plutizki and Kilian Guse. | $6.6M / Series A / Feb 15, 2021 | ||
| Ampacimon develops dynamic line rating systems for transmission and distribution systems operators. Ampacimon’s products address grid infrastructure challenges such as aging assets, transmissions congestion, renewable integration, interconnectors. | $4.7M / Venture - Series Unknown / Aug 26, 2020 |
Co-Investors
About Meusinvest (Noshaq)
Noshaq offers financial services to help businesses develop.
Meusinvest (Noshaq) Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Alain Balthazart
Investment Manager
|
|||
Gérôme Vanherf
Program Manager
|
|||
Joanna Tyrekidis
CEO of Noshaq Spin-Offs; Investment Manager
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Gaëtan Servais invest in?
Gaëtan Servais invests primarily in Health Care, Biotechnology and Medical startups, most often at Series A and Series C stage. Most of the 6 investments tracked by Shizune back companies in Belgium. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Gaëtan Servais?
Public channels for Gaëtan Servais include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Gaëtan Servais last invest?
The most recent investment recorded for Gaëtan Servais closed in Sep 2026. Shizune tracks 6 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
